Optretina

What Optretina does

Optretina (legal name Upretina) is a Spain-based telemedicine company operating a non-mydriatic retina screening platform that connects optical stores, corporate occupational health programs, and healthcare partners with registered retinologists for medical report review. Founded in 2013 and headquartered in Sant Cugat del Vallès, Barcelona, the company operates as an AEMPS-licensed medical device manufacturer and is compliant with EU Regulation 2017/745 (EU MDR) and Spanish Royal Decree 1591/2009, restricting its products to use by healthcare professionals.

The core product, UpRetina, is a telemedicine platform that performs retina screening without pupil dilation and routes results to registered retinologists with a maximum 48-hour response time. It is delivered as three tailored solutions: Para Ópticas (optical retailers), Para Empresas (corporate occupational health programs), and Para Partners Sanitarios (hospitals, insurers, and clinics). The company reports more than 500 collaborating centers across Spain and over 750,000 patients cumulatively reviewed. Leadership comprises co-founders Mark Ruiz (CEO), Miguel A. Zapata (Medical Director), and Dídac Royo (CTO), and a private workflow portal is available at app.optretina.com.

Revenue is generated through subscription and recurring service fees under a B2B2C model, distributed via direct sales to optical retailers and corporate buyers and via channel partnerships with healthcare organizations. Operations are limited to Spain, although the corporate website supports Spanish, English, German, Portuguese, and Catalan. The firm has not raised external capital beyond an early Hubraum relationship recorded in October 2013, and it operates with a 1-10 employee footprint consistent with a lean delivery model.

Name

Optretina

Legal name

Upretina

Website

https://optretina.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Optretina is a Spain-based, AEMPS-licensed telemedicine company providing non-mydriatic retina screening to optical stores, corporate occupational health programs, and healthcare partners, with medical reports reviewed by registered retinologists within 48 hours.

Ownership category

akta.pro rank

Product category

Telemedicine Retina Screening

NAICS

Medical and Diagnostic Laboratories (6215), Ophthalmic Goods Manufacturing (339115), Offices of Optometrists (62132)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Services-Medical Laboratories (8071)

akta.pro primary industry

Ophthalmology & Vision Telemedicine Platforms (HLALAGAL)

akta.pro secondary industries

Ocular Imaging & Diagnostic Testing Centers (HLAKAKAN), Optical Dispensing & Eyewear Devices (Frames, Lenses, Lens Edging/Finishing Equipment) (HLAHAJAD), Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging) (HLAFAKAI)

Keywords

• Retina screening services
• Telemedicine platform
• Non-mydriatic imaging
• Occupational health screening
• Preventive ophthalmology

Headquarters

HQ city

Sant Cugat Del Vallès

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Retina Screening Services: Optretina provides retina screening services through a B2B2C model, serving optical stores, companies for occupational health programs, and healthcare partners. The service includes non-mydriatic screening, medical report review by registered retinologists, and monitored response times up to 48 hours.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Optretina provides a telemedicine retina screening service through its UpRetina platform, connecting optical stores, companies running occupational health programs, and healthcare partners (hospitals, insurers, clinics) with licensed, registered retinologists. The offering centers on non-mydriatic retina screening (no pupil dilation required), professional medical report review by retinólogos colegiados, and monitored response times of up to 48 hours, delivered under AEMPS medical-device manufacturer licensing.

Product overview

Optretina offers UpRetina, a unified telemedicine platform for retina screening. The platform provides three tailored solutions: one for opticians (Para Ópticas), one for companies (Para Empresas), and one for healthcare partners (Para Partners Sanitarios). All solutions connect users with licensed retinologists for medical review and provide results within a maximum of 48 hours.

Differentiator

Problem solved

Functional benefit

Products and services

• UpRetina for Ópticas (Optical Stores) Telemedicine retina screening solution within the UpRetina platform, designed for optical store operators in Spain to add non-mydriatic retina screening and licensed-retinologist-reviewed medical reports to their retail customer offering as a B2B2C clinical service.
• UpRetina for Empresas (Corporate Occupational Health) Telemedicine retina screening solution within the UpRetina platform designed for enterprise occupational health programs, enabling companies in Spain to deploy workplace retina screening and receive medical reports reviewed by registered retinologists within a maximum of 48 hours.
• UpRetina for Partners Sanitarios (Healthcare Partners) Collaborative and distribution solution within the UpRetina platform for hospitals, health insurers, and clinics in Spain, allowing these healthcare partners to offer retina screening services adapted to their organization's needs, leveraging Optretina's AEMPS-licensed medical-device manufacturer status and registered retinologist network.

Quantifiable outcome

• 500+ collaborating centers (optical stores and companies) across Spain trust Optretina's retina screening
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators4 records

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• Heidelberg Engineering: Specialist in confocal laser ophthalmic imaging (Spectralis OCT, fundus imaging). Provides the high-end diagnostic devices that anchor many tele-retina workflows Optretina competes with or complements in clinical settings.
• Topcon Healthcare: Major ophthalmic imaging and healthcare IT vendor offering fundus cameras, OCT, and screening/connectivity solutions. Competes with Optretina in the tele-retina workflow at the device layer but as part of a much broader product portfolio.
• Carl Zeiss Meditec: Global leader in ophthalmic diagnostic devices (fundus imaging, OCT, perimetry). Overlaps with Optretina at the device/clinical workflow layer and represents a potential partner or competitor as tele-ophthalmology platforms scale.
• Nidek: Japanese ophthalmic equipment manufacturer producing fundus cameras, OCT, and screening devices. Overlaps with Optretina's hardware-enabled screening proposition, particularly in optical retail and clinical channels outside Spain.

Regional players

• Tomey (Tomey Corporation): Japanese ophthalmic device manufacturer with strong presence in Asia-Pacific, offering fundus cameras and OCT systems for screening programs. Regionally focused peer with overlapping screening use cases but limited direct competition in Spain.

Direct peers

• Optomed: Finland-based manufacturer of handheld and table-top retinal cameras with a connected screening platform targeting primary care, occupational health, and screening programs. Highly comparable in combining non-mydriatic hardware with tele-screening software for non-ophthalmologist operators.
• Intelligent Retinal Imaging Systems (IRIS): US-based tele-retinal screening platform that partners with optical retailers and primary care to deliver remote retinal evaluations for early disease detection. Direct comparable in business model, customer base (optical chains and occupational/clinical channels), and core offering of remote screening reviewed by remote specialists.
• iCare (formerly Centervue): iCare manufactures retinal imaging devices (including non-mydriatic fundus cameras) and screening software used by optometrists and screening programs globally. Comparable in targeting the same optometry and screening workflow that Optretina serves through its Ópticas channel.

Emerging players

• Eyenuk: AI-enabled diabetic retinopathy and eye disease screening company selling FDA-cleared autonomous screening. Comparable to Optretina's screening-as-a-service model for optical and clinical channels, but competes via AI grading rather than human retinologist review.
• Digital Diagnostics (Digital Diagnostic Inc.): Autonomous AI diagnostic company (IDx-DR for diabetic retinopathy) focused on point-of-care screening in primary care. Comparable as an emerging tele-screening alternative that may compete with or substitute for Optretina's specialist-reviewed model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/optretina
• Instagraminstagram.com/optretina
• Xx.com/optretina
• Facebookfacebook.com/OPTretina

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Optretina